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Motor Unit Number Estimation in Evaluating Disease Progression 
in Patients with Amyotrophic Lateral Sclerosis
We investigated the availability of motor unit number estimation (MUNE) as a quantitative 
method to assess the severity and clinical progression of amyotrophic lateral sclerosis (ALS). 
The 143 ALS patients were evaluated by statistical MUNE and the revised amyotrophic 
lateral sclerosis functional rating scale (ALSFRS-R). By using mean values of MUNE 
according to disease duration, regression equation between mean MUNE and disease 
duration was presented as a formula. The individual MUNE ratio was calculated by dividing 
individual MUNE value by mean MUNE value. All patients were classified into 2 groups 
(MUNE ratio <1 vs. MUNE ratio ≥1) according to the MUNE ratio. Comparison between the 
2 groups revealed that the patients in MUNE ratio <1 group or MUNE ratio ≥1 group were 
respectively assigned to rapid progression or slow progression. We recommended 
informative mean values of MUNE and best regression equation in ALS patients according 
to disease duration. These values allow us to evaluate the severity and rapidity of 
progression in ALS.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS), the most common adult-
onset motor-neuron disease, is pathologically characterized by 
progressive loss of the upper and lower motor neurons in the 
brainstem motor nuclei and the anterior horn of the spinal cord. 
This pattern of neurodegeneration produces progressive weak-
ness, muscular wasting, and spasticity. The disease starts seg-
mentally before it spreads and causes death from respiratory 
failure or infection a few years after its onset. However, the mo-
dalities of disease progression are diverse among patients (1). 
Diversities of the disease course in ALS make it difficult to give 
patients accurate information about the progress of the disease 
and to ascertain whether there is a beneficial effect of the treat-
ment to slow the progression of the disease. Nerve conduction 
study (NCS) and electromyography (EMG) have been used to 
diagnose ALS and are relatively accurate methods for diagnos-
ing ALS (2). But these methods do not reveal the severity of the 
disease and the rate of its progression. Therefore, a quantitative 
electrophysiological method is needed to monitor disease sever-
ity, rate of progression, and response to treatment. Motor unit 
number estimation (MUNE) can be a valuable tool for assessing 
ALS (3-5). MUNE is an electrophysiological technique that esti-
mates the number of functioning motor units in a given muscle 
or group of muscles (6, 7). MUNE is calculated by dividing the 
value of the maximal compound muscle action potential (CMAP) 
by the value of the average surface-recorded motor unit poten-
tial (SMUP) (3-8). Of the various MUNE techniques that essen-
tially obtain representative samples of SMUPs in different ways, 
the statistical method has been reported to be more represen-
tative of the actual distributions of motor units than the results 
obtained using other MUNE methods (8-14). A few clinical tri-
als have been performed in ALS patients and showed the reli-
ability and reproducibility of statistical MUNE (8-11). But, so far, 
the MUNE has been limitedly demonstrated in the diagnosis of 
ALS and evaluation of the severity of the disease. When analyzing 
the results of MUNE in ALS patients, we are usually confound-
ed about the clinical application of MUNE, e.g. which method, 
among the program determined MUNE (P-MUNE), number-
weighted MUNE (NW-MUNE), and size-weighted MUNE (SW-Ahn S-W, et al.  •  MUNE in ALS Progression
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MUNE), is clinically the most representative in ALS patients? 
How can we explain the results of MUNE to ALS patients?
  To better address the availability of MUNE as a quantitative 
method for assessing the severity and clinical progression of the 
disease in patients with ALS, we investigated the mean values 
of MUNE according to the disease duration in a wide range of 
ALS patients, and compared the electrophysiological rapidity of 
the progression by the MUNE ratio with the clinical rapidity of 
progression by ALSFRS.
 
MATERIALS AND METHODS
Patients 
Patients with definite or laboratory-supported probable ALS 
according to the revised El Escorial criteria were consecutively 
recruited from the ALS Clinic of the Seoul National University 
Hospital where the protocol was approved by the Institutional 
Review Board (H-1002-027-309) (2). We excluded patients who 
had a history of brain injury, stroke, diabetes, ulnar neuropathy, 
polyneuropathy and no potential in the abductor digiti minimi 
(ADM) muscle, which was confirmed by NCS/EMG, clinical his-
tory, laboratory examinations and, occasionally imaging study. 
Finally, 143 patients were enrolled and were evaluated by MUNE 
in bilateral ADM muscles (Table 1). The first manifestation of 
patients was respectively presented to be upper extremity weak-
ness in 70 patients, lower extremity weakness in 37, and dysar-
thria or dysphagia in 36 (Table 1). The mean disease duration 
was generally recorded by the patient’s statement of the number 
of months after onset of the first symptoms. Functional impair-
ment due to ALS was evaluated using the revised amyotrophic 
lateral sclerosis rating scale (ALSFRS-R), which consists of 12 
items that measure bulbar, upper extremity, lower extremity, 
and respiratory functions (15). The scores range from 0 (severe 
impairment) to 48 (normal functioning), with a low score indi-
cating greater impairment.
Motor unit number estimation
MUNE was performed with a commercially available version of 
the statistical MUNE method (Nicolet Biomedical, Inc., Madi-
son, WI, USA). Percutaneous stimulation of the ulnar nerve at 
the wrist was delivered by a flat bar electrode that was wrapped 
around the arm. The maximal compound muscle action poten-
tial (CMAP) of the ADM muscle was then recorded using surface 
electrodes. After obtaining a CMAP by supramaximal stimula-
tion, a sigmoid curve of the CMAP area was obtained as a func-
tion of increased stimulus intensity by delivering 30 computer 
controlled stimuli at 1 Hz, which increased in intensity by equal 
increments from just sub-threshold to just supramaximal inten-
sity. Three scan graphs were obtained sequentially by repeating 
the above procedure. The test areas of 4 segments were com-
posed in most patients. The sum of the test areas accounted for 
80% or more of the whole CMAP area in cases with 3 or fewer 
test areas. The test areas were selected according to the rules 
designed to ensure inclusion of the most neurogenically com-
pensated segments, thus indicating the presence of abnormally 
large MUPs because of compensatory reinnervation. Initially, 
we selected areas either with a consistent area gap exceeding 
10% of the maximal CMAP or with a gap exceeding 5% of the 
maximal CMAP that was flanked by more than 2 CMAP areas of 
the sample size on both the lower and upper sides in 3 consec-
utive scan graphs. On acquiring the first set of 30 submaximal 
CMAPs in the test area, each set of CMAPs was found to show a 
Table 1. Clinical characteristics of patients and mean values of the individual MUNE (P-MUNE, NW-MUNE, and SW-MUNE), ALSFRS-R and CMAP according to disease duration 
from onset to examination were measured
Parameters Total patients
Disease duration (months)
3-6 6-12 12-18 18-24 24-30 30-36
No. of patients 143 14 46 28 22 16 13
Sex (female:male)  54:89 6:8 16:30 9:19 9:13 9:7 5:8
Age (yr)   55.1 (±11.1)   53.6 (±10.6)   54.1 (±10.8) 56.0 (±9.3)   57.7 (±11.1)   56.2 (±13.3)   56.1 (±11.9)
Range of age (yr) 20-79 33-67 20-75 36-70 40-79 35-79 41-74
Mean disease duration (months)   17.1 (±10.0)   5.1 (±1.2)   9.4 (±1.8) 15.2 (±1.9) 21.2 (±2.1) 26.4 (±1.8) 34.1 (±1.9)
No. of patients by onset region
   (UE:LE:Bulbar)
70:37:36 5:6:3 23:12:11 15:6:7 13:7:2 8:2:6 4:2:7
ALSFRS-R 36.9 (±6.2) 43.4 (±2.1) 40.5 (±2.9) 38.1 (±3.9) 34.5 (±4.7) 29.9 (±4.8) 27.3 (±5.2)
Clinical rapidity of progression   0.72 (±0.27)   0.92 (±0.36)   0.79 (±0.28)   0.65 (±0.24)   0.65 (±0.25)   0.69 (±0.20)   0.61 (±0.16)
CMAP   5.9 (±3.2)   7.5 (±3.2)   6.4 (±2.8)   6.2 (±3.5)   5.1 (±2.6)   5.6 (±3.2)   4.5 (±3.4)
P-MUNE   55.2 (±38.9)   67.0 (±29.4)   63.3 (±43.1)   54.6 (±37.3)   50.5 (±35.0)   46.3 (±35.0)   44.8 (±41.7)
NW-MUNE   41.3 (±26.3)   53.2 (±22.5)   47.0 (±27.8)   42.9 (±26.8)   37.6 (±23.1)   32.1 (±21.6)   30.4 (±25.5)
SW-MUNE   33.2 (±24.2)   45.3 (±22.3)   38.8 (±25.7)   34.5 (±23.8)   30.4 (±22.4)   24.9 (±20.0)   20.0 (±19.6)
Datas are expressed as mean±standard deviation. 
UE, LE and Bul bar refer to the patients whose onset region is respectively upper extremity, lower extremity and bulbar area.
MUNE, motor unit number estimation; ALS, amyotrophic lateral sclerosis; P-MUNE, Program determined MUNE; NW-MUNE, number-weighted MUNE; SW-MUNE, Size-weighted 
MUNE; ALSFRS-R, revised amyotrophic lateral sclerosis functional rating scale; CMAP, compound motor action potential; Clinical rapidity of progression=(48–ALSFRS-R)/disease 
duration.Ahn S-W, et al.  •  MUNE in ALS Progression
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poisson distribution that skewed slightly to lower amplitude. 
Stimuli were delivered at 2 Hz, and subsequent sets of the 30 
stimuli were delivered in the same manner until the amplitude 
of the SMUP obtained by each set showed a variation of less than 
10%. SW-MUNE was calculated as proposed by Olney et al. (12), 
and NW-MUNE as described by Shefner et al. (13). However, it 
was the limitation of MUNE that MUNE was performed mainly 
in the hand muscle and therefore MUNE parameters might not 
reflect the overall functional status of ALS patients. To reduce 
this limitation, we performed MUNE in bilateral hand muscle, 
and used the average values in this study.
Statistical analysis
SPSS v17.0 was used for data analysis and frequency tables were 
generated for the demographic data, ALSFRS, and mean values 
of the individual MUNE (including P-MUNE, NW-MUNE, and 
SW-MUNE) (Table 1). The correlations of the individual MUNE 
with disease duration and ALSFRS-R were respectively investi-
gated by using the Pearson’s correlation coefficient for samples, 
and they were confirmed to be normal distribution by using 
Kolmogorov-Smirov test before performing Pearson’s correla-
tion. According to the disease duration (up to 6, 12, 18, 24, 30, 
and 36 months), clinical characteristics, mean values of ALS-
FRS-R, individual MUNE, and rapidity of disease progression 
were presented (Table 1) and best regression equation between 
disease duration and mean SW-MUNE was analyzed to predict 
mean SW-MUNE in any disease duration (Estimated mean SW-
MUNE=48.03–0.85×[disease duration]). Four patients with dis-
ease duration over 36 months among 143 patients were exclud-
ed from this procedure. The MUNE ratios of patients were cal-
culated by dividing the individual SW-MUNE value by estimat-
ed mean SW-MUNE using regression equation (MUNE ratio= 
measured SW-MUNE/estimated mean SW-MUNE using regres-
sion equation). Patients were classified into 2 groups according 
to the results of the MUNE ratio, i.e., (MUNE ratio <1) vs. (MUNE 
ratio ≥1). An assessment of the clinical rapidity of disease pro-
gression by ALSFRS-R was made as follows. Rapidity of progres-
sion=(48–ALSFRS-R)/disease duration (16). The ALSFRS-R, SW-
MUNE, CMAP, SW-SMUP, clinical rapidity of progression by 
ALSFRS-R, and MUNE ratio were compared between these 2 
groups by using unpaired t-test. A significance level was set at 
P<0.01.
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Fig. 1. Correlations of size-weighted MUNE with disease duration (A), disease duration with ALSFRS-R (B), size-weighted MUNE with ALSFRS-R (C), and MUNE ratio with rate of 
progression by ALSFRS-R (D) were statistically significant (P value <0.01).
MUNE, motor unit number estimation; ALSFRS-R, revised amyotrophic lateral sclerosis functional rating scale; MUNE ratio=(individual SW-MUNE)/(estimated mean SW-MUNE 
using regression equation).Ahn S-W, et al.  •  MUNE in ALS Progression
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RESULTS
We evaluated 143 patients and obtained 286 results of MUNE. 
All patients were evaluated in the bilateral ADM muscles. The 
age of the participants ranged from 20 to 79 yr (mean age: 55.1 yr, 
SD±11.1), and 89 participants (62.2%) were male (Table 1). The 
mean disease duration, which is generally the patient’s statement 
of the number of months after onset of the first symptoms, was 
17.1 months (SD±10.0) (Table 1). The mean score of ALSFRS-R 
in all ALS patients was 36.9 (SD±6.2). The individual mean values 
of P-MUNE, NW-MUNE, and SW-MUNE were 55.2 (SD±38.9), 
41.3 (SD±26.3), and 33.2 (SD±24.2), respectively (Table 1).
  The individual value of MUNE and CMAP were found to cor-
relate with disease duration and ALSFRS-R. Among them, S-
MUNE was statistically the most significant (Pearson correla-
tion efficient with disease duration and ALSFRS-R, respectively: 
-0.329 [P<0.001]; 0.576 [P<0.001]) (Fig. 1). Similarly, these sig-
nificant correlations were also detected when the age was con-
sidered the control variable.
  The mean values of the individual MUNE and ALSFRS-R ac-
cording to the disease duration (up to 6, 12, 18, 24, 30, and 36 
months) were also presented. The mean values of MUNE showed 
a gradually decreasing pattern as the disease duration increas-
ed (Table 1, Fig. 2). From mean disease duration and mean SW-
MUNE, regression equation was analyzed (Estimated mean SW-
MUNE=48.03–0.85×[disease duration]) (Fig. 2) and MUNE ratio 
were calculated by dividing individual patient’s SW-MUNE by 
estimated mean SW-MUNE using regression equation for the 
individual ALS patients. The MUNE ratio were statistically cor-
related with the clinical rapidity of disease progression by ALS-
FRS (Pearson’s correlation coefficient=–0.449; P<0.001) (Fig. 1). 
Using the cut-off limit for the rapidity of progression by the MUNE 
ratio in ALS patients, 79 patients were assigned to the rapid pro-
gression group (MUNE ratio <1). The remaining 64 patients were 
assigned to the slow progression group (MUNE ratio ≥1) (Table 
2). The mean MUNE ratio was 0.47 (SD±0.26) in the rapid pro-
gression group and 1.67 (SD±0.53) in the slow progression group 
(Table 2). The clinical rapidity of progression by ALSFRS-R, SW-
MUNE, ALSFRS-R, MUNE ratio and CMAP were compared be-
tween the 2 groups, and significant differences were detected by 
using unpaired t-test. The electrophysiological rapidity of pro-
gression by MUNE ratio was coincident with the difference of 
CMAP and the clinical rapidity of progression by ALSFRS (Fig. 1, 
Table 2). 
DISCUSSION
The diagnosis of ALS is usually made by clinical manifestations 
and NCS/EMG, which can provide accurate diagnostic informa-
tion on the widespread denervation potentials (17). However, 
the quantification of the disease severity is not easy (2). The loss 
of motor unit in ALS is gradually progressive as the disease ad-
vances. Therefore, we can evaluate and quantify the disease pro-
gression through the number of motor units (3, 4). MUNE is the 
number of functioning motor units in a given muscle or group 
of muscles that can be used to monitor disease progression or 
severity of disease in ALS (3, 4). A few longitudinal studies using 
MUNE in some ALS patients have been reported and suggested 
that MUNE decreases as the disease progresses and that MUNE 
is a very reliable and reproducible method in ALS (10-14). How-
Table 2. Clinical characteristics, SW-MUNE, ALSFRS-R, Clinical rapidity of progression, 
MUNE ratio and asymmetric index for patients in rapid progression group (MUNE ratio 
<1) and slow progression group (MUNE ratio ≥1)
Parameters
MUNE ratio (SW-MUNE/estimated Mean SW-MUNE) 
Rapid progression 
group (MUNE  
ratio <1)
Slow progression 
group (MUNE  
ratio ≥1)
Unpaired 
t-test
No. of patients  79  64 
Sex (female:male) 32:47 22:42
Age (yr)   56.2 (±11.2)   53.9 (±10.9)   P=0.218
Disease duration (months) 17.2 (±9.1)   17.1 (±11.2)   P=0.980
ALSFRS-R 35.3 (±6.8) 38.0 (±6.2)   P=0.016
SW-MUNE   16.2 (±10.2)   54.3 (±18.3)   P<0.001
SMUP   271 (±208)   229 (±159) P=0.61
CMAP   5.35 (±2.99)   6.77 (±3.17)   P<0.001
MUNE ratio   0.47 (±0.26)   1.67 (±0.53)   P<0.001
Clinical rapidity of progression    0.79 (±0.27)   0.64 (±0.24)   P=0.001
Data are expressed as mean values (±standard deviation).
MUNE, motor unit number estimation; ALS, amyotrophic lateral sclerosis; P-MUNE, 
Program determined MUNE; NW-MUNE, number-weighted MUNE; SW-MUNE, Size-
weighted MUNE; SMUP, surface-recorded motor unit potential; ALSFRS-R, revised 
amyotrophic lateral sclerosis functional rating scale; CMAP, compound motor action 
potential; Clinical rapidity of progression=(48–ALSFRS-R)/disease duration, MUNE 
ratio=(individual SW-MUNE)/(estimated mean SW-MUNE using regression equation).
Fig. 2. MUNE gradually decreases as disease advanced in ALS, and size-weighted 
MUNE shows the most significant correlation with disease duration. From mean disease 
duration and mean SW-MUNE, regression equation was analyzed (Estimated mean 
SW-MUNE=48.03–0.85×[disease duration]).
P-MUNE, Program determined MUNE; NW-MUNE, number-weighted MUNE; SW-MUNE, 
Size-weighted MUNE ALSFRS-R, revised amyotrophic lateral sclerosis functional rating 
scale.
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ever, there has been no document on mean values of MUNE 
according to the disease duration in a wide range of ALS patients. 
This study demonstrates that statistical MUNE highly correlates 
with disease duration and ALSFRS-R. The clinical correlation 
can be improved by applying a size- or number-weighted mod-
ification. Among all modalities of MUNE and CMAP, SW-MUNE 
showed the most significant correlation with disease duration 
and ALSFRS-R. The mean values of SW-MUNE showed most 
significantly decreasing patterns according to disease duration, 
therefore, the study also shows that SW-MUNE is more practi-
cable than P-MUNE, NW-MUNE or CMAP, even though CMAP, 
which is a relatively simple measurement, also decreased signif-
icantly over disease course.
  It is most suggestive that this study presented mean values of 
MUNE according to disease duration, since it improved the prac-
ticability of MUNE. After individual evaluation of the ALS patients 
by MUNE, these results can be compared with the mean values 
of the large number of ALS patients presented in this study. If the 
result of the patient’s MUNE was greater than the mean value of 
all ALS patients with the equivalent disease duration, it could be 
supposed that the patient has a more favorable course compared 
with the average of all ALS patients. Conversely, if the result of 
the patient’s MUNE was lower than the mean value of all ALS 
patients with the equivalent disease duration, it could be sup-
posed that the patient has a faster disease progression than the 
average of all ALS patients. We assigned all patients to either the 
rapid (MUNE ratio <1) or slow progression group (MUNE ratio 
≥1) on the basis of the MUNE ratio of SW-MUNE. The results 
(Fig. 1, Table 2) revealed that the MUNE ratio of SW-MUNE was 
coincident with the clinical rapidity of disease progression by 
ALSFRS, and the statistical differences were showed in CMAP, 
ALSFRS-R and MUNE ratio. Therefore, supposition of the rapid-
ity of disease progression or severity of the disease in ALS patients 
is possible by comparing the results of individual MUNE with 
the estimated mean MUNE according to the disease duration.
  The limitation of the present study is that MUNE of patients 
was performed in only ADM muscle, and so the results may be 
restricted to hand function in ALS and we cannot conclusively 
assert that the same MUNE value in different patients represents 
the same disease course or severity in patients. However the ALS 
is generalized disease simultaneously involving upper extremi-
ty, lower extremity and cranial muscle, therefore hand muscle 
weakness can represent the severity of generalized weakness to 
some degree. Of course, further studies over multiplicate MUNE, 
which measures upper extremity, lower extremity and cranial 
muscle in ALS patients, are required in the future.
  In conclusion, the mean values of MUNE and regression equa-
tion assessed in a wide range of ALS patients are very informa-
tive in that the results can be compared with MUNE of individ-
ual ALS patient, which allows physicians to estimate the disease 
severity and rapidity of progression in ALS patients. And its com-
bination with other measurements, such as CMAP or clinical 
rapidity of ALSFRS-R, may enhance overall prognostic accuracy 
in ALS.
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